• Eli Lilly & Company, the maker of anti-amyloid Alzheimer’s treatments, was expecting its experimental drug donanemab to be approved by the FDA this month.
• However, the FDA has said it will hold a panel with external advisors to evaluate the safety and efficacy of donanemab before it makes a decision later this year.
• Although the FDA’s decision was a surprise, some experts say a more cautious approach would be beneficial for patients, considering the drug is in early trials and there is little evidence of its benefits.

By Finn Cohen on March 13, 2024 — Fact checked by Jill Seladi-Schulman, Ph.D.

read full article